HealthQuill pfizer
Pfizer’s haemophilia A gene therapy has reduced bleeding rates in patients during an end-stage trial, according to a company statement.
Drugs Health Pharma

Pfizer’s haemophilia A gene therapy cuts bleeding rates during trials

HQ Team July 25, 2024: Pfizer’s haemophilia A gene therapy has reduced bleeding rates in patients during an end-stage trial, according to a.

Read More
The European Medicines Agency has allowed marketing authorisation for the Covid-19 variant vaccine made by Pfizer and BioNTech SE for children aged six months and older, according to a joint statement.
Drugs Health Pharma

Pfizer, BioNTech gets EMA marketing nod for variant Covid-19 vaccine

The European Medicines Agency has allowed marketing authorisation for the Covid-19 variant vaccine made by Pfizer and BioNTech SE for children aged six.

Read More
Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to a statement.
Drugs Health Pharma

Pfizer’s blood cancer trial data shows survival of more than 2 years 

Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to.

Read More
Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.
Drugs Health Pharma

Pfizer’s Duchenne muscular dystrophy trial fails to meet primary goal

Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.

Read More
Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression after five years, according to company data.
Drugs Health Pharma

Pfizer’s drug helps people with rare lung cancer live longer, data shows

Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression.

Read More
Pfizer Inc., announced a $1.5 billion “multi-year” savings plan to cut costs of goods sold, on top of a similar $4 billion initiative unveiled in October last year, when sales of its Covid-19 vaccine plummeted.
Drugs Health Pharma

Pfizer Inc. unveils a new $1.5 billion plan to cut costs as vaccine sales fall

Pfizer Inc., announced a $1.5 billion “multi-year” savings plan to cut costs of goods sold, on top of a similar $4 billion initiative.

Read More
Pfizer and AstraZeneca will invest about $1 billion separately in France to set up and expand facilities, Finance Minister Bruno Le Maire said, according to a publicly-funded television network, France 24.
Drugs Health Pharma

Pfizer, AstraZeneca to invest close to $1 billion in France to expand

HQ Team May 13, 2024: Pfizer and AstraZeneca will invest about $1 billion separately in France to set up and expand facilities, Finance.

Read More
A young boy, treated for a rare genetic disease, died during a mid-stage clinical trial conducted by Pfizer, according to a statement posted by a non-profit group on its website quoting a company statement.
Drugs Health Pharma

Boy dies during Pfizer’s clinical trial probing rare genetic disease

HQ Team May 8, 2024: A young boy, treated for a rare genetic disease, died during a mid-stage clinical trial conducted by Pfizer,.

Read More
The US health regulator has approved Pfizer’s drug to treat cervical cancer patients whose disease has progressed beyond the chemotherapy stage.
Drugs Health Pharma

Pfizer gets full US regulatory approval for cervical cancer drug

HQ Team April 30, 2024: The US health regulator has approved Pfizer’s drug to treat cervical cancer patients whose disease has progressed beyond.

Read More
The European Commission has granted Pfizer Inc., marketing authorisation for a drug to treat adult patients with intra-abdominal infections, hospital-acquired pneumonia and complex urinary tract infections.
Drugs Health Pharma

EC marketing nod for Pfizer drug to fight antimicrobial resistance

HQ Team April 22, 2024: The European Commission has granted Pfizer Inc., marketing authorisation for a drug to treat adult patients with intra-abdominal.

Read More
X